<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112110</url>
  </required_header>
  <id_info>
    <org_study_id>AI443-109</org_study_id>
    <secondary_id>2013-004645-17</secondary_id>
    <nct_id>NCT02112110</nct_id>
  </id_info>
  <brief_title>Absolute Bioavailability of BMS-791325</brief_title>
  <official_title>Study of the Absolute Oral Bioavailability of BMS-791325 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of
      BMS-791325 relative to 100 µg IV infusion of [13C]-BMS-791325.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: Other: Protocol is designed to assess the absolute bioavailability of 150 mg
      (2x75 mg tablets) BMS-791325 administered orally
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">May 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute oral bioavailability (F) of BMS-791325</measure>
    <time_frame>48 hours from time of oral dosing</time_frame>
    <description>Absolute bioavailability of 150 mg (2x75 mg tablets) BMS-791325 administered orally will be established by calculating the ratio of the dose normalized AUC(INF) of oral dose with that of 100 µg IV infused dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of BMS-791325 by the occurrence of AEs and SAEs, abnormalities in vital sign measurements exceeding pre-defined thresholds, findings on ECGs and PEs, and abnormalities and marked abnormalities in clinical laboratory test.</measure>
    <time_frame>Day 1 predose and 2 hours post-dose, Day 2 and Day 3</time_frame>
    <description>Serious adverse events (SAEs)
Adverse events (AEs)
Physical examinations (PEs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal plasma half-life (T-HALF) of BMS-791325 (oral dose) and [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total clearance (CLT) of [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution at steady-state (Vss) of [13C]-BMS-791325 (IV dose)</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 1.75, 1.97, 2, 2.125, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 12, 16, 24, 28, 32, 36 and 48 hours post oral dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>BMS-791325 (oral) and [13C]-BMS-791325 (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-791325 single dose tablet orally and [13C]-BMS-791325 single dose solution intravenously on specific days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-791325</intervention_name>
    <arm_group_label>BMS-791325 (oral) and [13C]-BMS-791325 (IV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[13C]-BMS-791325</intervention_name>
    <arm_group_label>BMS-791325 (oral) and [13C]-BMS-791325 (IV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          1. Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination, ECGs, and clinical laboratory determinations

          2. Men and women ages 18 to 49 years, inclusive

          3. Women of childbearing potential (WOCBP) must not be pregnant or breastfeeding

               -  WOCBP and men who are sexually active with WOCBP must agree to follow protocol
                  mandated instructions for method(s) of contraception during and after the study

        Exclusion Criteria:

          1. Any significant acute or chronic medical illness

          2. Any current or recent gastrointestinal disease or surgery that could impact upon the
             absorption of study drug

          3. Inability to tolerate oral medication

          4. Inability to be venipunctured and/or tolerate venous access

          5. Use of tobacco-containing or nicotine-containing products within 6 months

          6. Recent (within 6 months of study drug administration) drug or alcohol abuse as defined
             in Diagnostic and Statistical Manual of Mental Disorders (4th Edition)(DSM IV),
             Diagnostic Criteria for Drug and Alcohol Abuse

          7. Any of the following on 12-lead electrocardiogram (ECG) prior to study drug
             administration at screening or Day -1, confirmed by repeat

        i)PR ≥ 210 msec

        ii)QRS ≥ 120 msec

        iii)QT ≥ 500 msec

        iv)QTcF ≥ 450 msec

        v)Second or third degree heart block

        h) Positive urine screen for drugs of abuse

        i) Positive blood screen for hepatitis C antibody, hepatitis B surface antigen, r HIV-1, -2
        antibodies

        j) Any of the following screening or Day -1 laboratory results outside the ranges specified
        below as defined by the laboratory, confirmed by repeat analysis:

        i)Serum creatinine &gt; upper limit of normal (ULN)

        ii)Alanine aminotransferase (ALT) &gt; ULN

        iii)Aspartate aminotransferase(AST) &gt; ULN

        iv)Total bilirubin &gt; ULN

        k) History of any significant drug allergy (such as anaphylaxis or hepatotoxicity)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nottingham</city>
        <state>Nottinghamshire</state>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2014</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

